Skip to main content

Table 6 Correlation between Lp-PLA2 level and socio-clinical parameters, Framingham risk score (2008), and liver stiffness score at baseline and at 12 weeks post-treatment

From: The effect of hepatitis C virologic clearance on cardiovascular disease biomarker lipoprotein-associated phospholipase A2 and its relation to serum lipids

Studied parameter

Lp-PLA2 (ng/ml)

Pre-treatment correlations

Post-treatment correlations

r

p

R

p

Age

0.350

0.001

0.409

<0.001

BMI (kg/m2)

0.331

0.001

0.258

0.014

FBG (mg/dl)

0.353

0.001

0.412

<0.001

HbA1c

0.332

0.001

0.403

<0.001

Platelets (103/훍l)

−0.225

0.033

−0.229

0.03

AST (IU/l)

0.188

0.076

0.296

0.005

ALT (IU/l)

0.099

0.355

0.033

0.76

Albumin (g/dl)

−0.336

0.001

−0.31

0.003

LDL (mg/dl)

0.142

0.182

0.197

0.062

Total cholesterol (mg/dl)

0.077

0.468

0.043

0.689

HDL (mg/dl)

−0.096

0.366

−0.284

0.007

Framingham score

0.669

<0.001

0.677

<0.001

Liver stiffness score (kPa)

0.157

0.139

0.276

0.008

  1. Abbreviations: Lp-PLA2, lipoprotein-associated phospholipase A2; BMI, body mass index; FBG, fasting blood glucose; HbA1c, hemoglobin A1c; AST, aspartate transaminase; ALT, alanine transaminase; LDL, low-density lipoprotein; HDL, high-density lipoprotein